Healthcare >> CEO Interviews >> October 25, 2004
JERRY McMAHON was appointed Chief Executive Officer of NeoRx Corporation
in May 2004 and Chairman of the Board of Directors a month later.
Previously, he was President of SUGEN, Inc., a biopharmaceutical company
focused on the discovery and development of novel, targeted small-
molecule drugs. At SUGEN, Dr. McMahon played a key role in the discovery
and development of several innovative cancer products, including
SU-11248, a multi-targeted protein kinase inhibitor for the treatment of
advanced cancers, now in Phase III trials with Pfizer. SUGEN was
acquired by Pharmacia in 1999, which subsequently was acquired by Pfizer
in 2003. Dr. McMahon was instrumental in providing transition
leadership, stability and oversight for SUGEN programs and employees
through these acquisitions. Prior to his role at SUGEN, which he joined
in 1993, Dr. McMahon held several R&D management positions at Sandoz
Pharmaceuticals (now Novartis), where his responsibilities included the
establishment of external collaborations and the development of
corporate alliances within the US and Europe. Dr. McMahon has
contributed to more than 100 scientific publications and was a Staff
Scientist and Principal Investigator at the Massachusetts Institute of
Technology and Tufts University School of Medicine early in his career.
He holds a BS in Biology and a PhD in Biochemistry from Rensselaer
Polytechnic Institute. Profile
initiatives.
Dr. McMahon: NeoRx is a company that has been focused on generating
innovative therapeutics for quite a
